[go: up one dir, main page]

WO2008110813A3 - Système de libération contrôlée - Google Patents

Système de libération contrôlée Download PDF

Info

Publication number
WO2008110813A3
WO2008110813A3 PCT/GB2008/000891 GB2008000891W WO2008110813A3 WO 2008110813 A3 WO2008110813 A3 WO 2008110813A3 GB 2008000891 W GB2008000891 W GB 2008000891W WO 2008110813 A3 WO2008110813 A3 WO 2008110813A3
Authority
WO
WIPO (PCT)
Prior art keywords
controlled release
release system
functional moiety
release
allows
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2008/000891
Other languages
English (en)
Other versions
WO2008110813A2 (fr
Inventor
James Davis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nottingham Trent University
Original Assignee
Nottingham Trent University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nottingham Trent University filed Critical Nottingham Trent University
Priority to EP08718733A priority Critical patent/EP2136845A2/fr
Publication of WO2008110813A2 publication Critical patent/WO2008110813A2/fr
Publication of WO2008110813A3 publication Critical patent/WO2008110813A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/559—Redox delivery systems, e.g. dihydropyridine pyridinium salt redox systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6957—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a device or a kit, e.g. stents or microdevices
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/202—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring the aromatic ring being a naphthalene
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/017—Esters of hydroxy compounds having the esterified hydroxy group bound to a carbon atom of a six-membered aromatic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une molécule qui comprend une fraction de liaison attachée à une fraction fonctionnelle par une liaison transformable électrochimiquement. L'introduction d'un potentiel électrique permet la libération de la fraction fonctionnelle. L'invention permet la libération contrôlée d'agents biologiquement actifs, d'antidotes, de parfums ou d'agents détectables, par exemple.
PCT/GB2008/000891 2007-03-15 2008-03-14 Système de libération contrôlée Ceased WO2008110813A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP08718733A EP2136845A2 (fr) 2007-03-15 2008-03-14 Système de libération contrôlée

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0705023.0A GB0705023D0 (en) 2007-03-15 2007-03-15 Controlled release system
GB0705023.0 2007-03-15

Publications (2)

Publication Number Publication Date
WO2008110813A2 WO2008110813A2 (fr) 2008-09-18
WO2008110813A3 true WO2008110813A3 (fr) 2009-04-30

Family

ID=38008507

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2008/000891 Ceased WO2008110813A2 (fr) 2007-03-15 2008-03-14 Système de libération contrôlée

Country Status (3)

Country Link
EP (1) EP2136845A2 (fr)
GB (1) GB0705023D0 (fr)
WO (1) WO2008110813A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114163448A (zh) * 2021-11-11 2022-03-11 北京大学深圳研究生院 一种基于萘并五元杂环苯并五元杂环的主体材料及其制备方法与有机发光器件

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002013671A2 (fr) * 2000-08-14 2002-02-21 Pharmacia Corporation Systeme de liberation (d'administration) de medicaments
WO2006044795A2 (fr) * 2004-10-14 2006-04-27 Trustees Of Tufts College Polymeres aptes a la degradation electrochimique

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002013671A2 (fr) * 2000-08-14 2002-02-21 Pharmacia Corporation Systeme de liberation (d'administration) de medicaments
WO2006044795A2 (fr) * 2004-10-14 2006-04-27 Trustees Of Tufts College Polymeres aptes a la degradation electrochimique

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JAFFAR M ET AL: "Prodrugs for targeting hypoxic tissues: regiospecific elimination of aspirin from reduced indolequinones", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 9, no. 1, 1 January 1999 (1999-01-01), pages 113 - 118, XP004154788, ISSN: 0960-894X *
JAFFAR MOHAMMED ET AL: "Quinone bioreductive prodrugs as delivery agents", CURRENT DRUG DELIVERY, BENTHAM SCIENCE PUBLISHERS, HILVERSUM, NL, vol. 1, no. 4, 1 October 2004 (2004-10-01), pages 345 - 350, XP008098116, ISSN: 1567-2018 *
LEWIS T W ET AL: "Electrofunctional polymers: Their role in the development of new analytical systems", ANALYST 1999 GB, vol. 124, no. 3, 1999, pages 213 - 219, XP002502068, ISSN: 0003-2654 *
SOLSONA IMMA ANDORRA ET AL: "Metabolic mimics: thiol responsive drug release.", JOURNAL OF COLLOID AND INTERFACE SCIENCE 15 OCT 2006, vol. 302, no. 2, 15 October 2006 (2006-10-15), pages 698 - 701, XP005644259, ISSN: 0021-9797 *
THOROGOOD C A ET AL: "Identifying quinone-like species on the surface of graphitic carbon and multi-walled carbon nanotubes using reactions with 2,4-dinitrophenylhydrazine to provide a voltammetric fingerprint", NEW JOURNAL OF CHEMISTRY 2007 GB, vol. 31, no. 6, 2007, pages 958 - 965, XP002502067, ISSN: 1144-0546 1369-9261 *
WEERAPREEYAKUL N ET AL: "REDUCTIVE AND BIOREDUCTIVE ACTIVATION IS CONTROLLED BY ELECTRONIC PROPERTIES OF SUBSTITUENTS IN CONFROMATIONALLY-CONSTRAINED ANTICANCER DRUG DELIVERY SYSTEMS", MEDICINAL CHEMISTRY RESEARCH, BIRKHAEUSER, BOSTON, US, vol. 10, no. 3, 1 January 2000 (2000-01-01), pages 149 - 163, XP009078359, ISSN: 1054-2523 *

Also Published As

Publication number Publication date
EP2136845A2 (fr) 2009-12-30
WO2008110813A2 (fr) 2008-09-18
GB0705023D0 (en) 2007-04-25

Similar Documents

Publication Publication Date Title
WO2010012442A3 (fr) Dérivé de benzènedicarboxamide insecticide
AU2010246102A8 (en) Pesticidal compositions
WO2006002840A3 (fr) Formulations de suspensions aerosol contenant tg 227 ea ou tg 134 a en tant qu'agent propulseur
WO2008070462A3 (fr) N-oxydes d'analogues 4,5-époxy-morphinanium
UA101346C2 (ru) 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и 2-фенилциклогексан-1,3,5-трионы как гербициды
WO2007136969A3 (fr) Stents polymères bioabsorbables renforcés par du magnésium
WO2008064353A3 (fr) Analogues 4,5-époxy-morphinanium saturé en position 7 et 8
HK1208227A1 (en) Novel tetragalnac containing conjugates and methods for delivery of oligonucleotides
WO2008109142A3 (fr) ARNpi ET UTILISATIONS CORRESPONDANTES
MA29816B1 (fr) Composes de benzimidazole thiophene
WO2007106746A3 (fr) Formulations d'écallantide
WO2009042064A3 (fr) Conjugués nucléoside phosphate oligomères
CL2007001919A1 (es) Compuestos derivados de 18-metil-15b,16b-metilen-19-nor-20-espirox-4-en-3-onas; composicion farmaceutica que comprende a dichos compuestos, utiles como anticonceptivos.
WO2006089119A3 (fr) Adhesif biologique
WO2009156090A3 (fr) Dérivés sulfurés de 1-azinyl-pyrazole utilisés en tant qu'insecticides
MY140739A (en) 2, 6-quinolinyl derivatives, processes for preparing them and their uses
WO2007138562A3 (fr) Compositions de parfum concentrée
WO2009058387A3 (fr) Conjugués anti-infectieux d'oligomère et de nitroimidazole
WO2009103813A3 (fr) Compositions fongicides contenant du 3'-bromo-2,3,4,6'-tétraméthoxy-2'-6-diméthylbenzophénone
TW200621160A (en) Anti-termite agent
WO2008110813A3 (fr) Système de libération contrôlée
WO2008107771A3 (fr) 2',3'-di-o-acyl-5-fluoronucléosides
WO2009085310A8 (fr) Compositions pharmaceutiques à libération prolongée contenant du zolpidem
WO2010017386A3 (fr) Surfaces antimicrobiennes
PL2004149T3 (pl) Preparaty farmaceutyczne zawierające leflunomid

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08718733

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008718733

Country of ref document: EP